As I understand it, yes.
Could I add, though, that one of the challenges—and I refer back to the work done in the Senate committee—is that these are global trials involving multiple companies, multiple countries, 5,000, 10,000, or 12,000 patients, and multiple sites across Canada. One of the things to come back to, because it relates to Ms. Adams' question, is to ensure that we have harmonization of research ethics boards or simplification of that, so that everybody has the same standards and the same research protocols and so on and so forth.